Dr. Hongrui Meng | Neuroscience; Pharmaceutical science | Best Researcher Award

Principal investigator at Institute of Neurosciecne, Soochow University, China

Dr. Hongrui Meng is a distinguished neuroscientist and professor at the Institute of Neuroscience, Soochow University, China. With expertise in molecular neurology and neurodegenerative diseases, Dr. Meng has led numerous pioneering studies investigating mitochondrial dysfunction and protein aggregation in Parkinson’s disease and amyotrophic lateral sclerosis. He is the founder of the Laboratory of Molecular Neurology at Soochow University, where he leads an interdisciplinary research team. His work bridges basic research and clinical innovation, contributing significantly to the understanding and potential treatment of neurological disorders.

Profile

ORCID

Education

Dr. Meng earned his Ph.D. in Behavioural Neuroscience from the Hamamatsu University School of Medicine in Japan. He later undertook postdoctoral training in molecular neurobiology and human genetics at Juntendo University in Tokyo. These formative experiences shaped his career in experimental neuroscience and laid the foundation for his ongoing research into the genetic and cellular basis of neurodegenerative diseases. His educational journey reflects both academic excellence and a global outlook on neuroscience research.

Experience

Dr. Meng began his academic career as an assistant professor at Juntendo University in the Department of Research for Neurodegenerative Diseases and Dementia. In 2020, he became a full professor and established the Laboratory of Molecular Neurology at Soochow University. Under his leadership, the lab has become a prominent hub for mitochondrial and neuroinflammation research. He has completed major projects funded by the Japan Society for the Promotion of Science and currently oversees ongoing grants supported by the Natural Science Foundation of China and Suzhou’s Science and Technology Program. He also collaborates with pharmaceutical companies to develop neuroprotective drugs and wearable devices for clinical monitoring.

Research Interest

Dr. Meng’s research interests focus on four major themes: protein misfolding and aggregation, mitochondrial dysfunction, glial cell behavior, and innovative therapeutic strategies. He explores how mitochondrial stress triggers α-synuclein accumulation, how glial cells influence neuronal survival, and how small molecule therapies can target these pathways. His lab uses model organisms such as Drosophila and mice, combined with cellular and genetic tools, to identify therapeutic targets and understand disease mechanisms. He is particularly interested in the roles of innate immune pathways and mitochondrial quality control in neurodegeneration.

Awards and Recognition

Dr. Meng is currently nominated for the “Excellence in Research Award,” reflecting his significant contributions to neuroscience. His patents, including a 2024 innovation for miRNA detection (ZA202400208, South Africa), demonstrate his technological ingenuity. He serves as an editorial board member for the Journal of Integrative Neuroscience and is an expert reviewer for national academic theses. He is also a member of several leading scientific societies, including the Chinese Neuroscience Society, the Japan Neuroscience Society, and the Molecular Biology Society of Japan. His ongoing collaborations with industry highlight his commitment to translational research and public impact.

Selected Publications

Dr. Meng has published extensively in high-impact international journals. Below are seven selected works:

1. Long X., Wang Y., Meng H. (2025). “Dicer Is Involved in Cytotoxicity and Motor Impairment Induced by TBPH Deficiency.” Current Issues in Molecular Biology, 47(6): 442.

2. Miao Y., Meng H. (2024). “Alpha-Synucleinopathy Disrupts Microglial Homeostasis in Parkinson’s Disease.” Cell Communication and Signaling, 22(1): 31.

3. Sun Y., Jiang M., Long X., et al., Meng H. (2024). “Transcriptomic Analysis of Lipid Metabolism in Alzheimer’s Disease.” Journal of Molecular Neuroscience, 74(2): 55.

4. Ikeda A., Meng H., et al. (2024). “CHCHD2 P14L Alters Calcium Homeostasis in ALS.” PNAS Nexus, 3(8): pgae319.

5. Long X., Du H., Jiang M., Meng H. (2023). “A Simple Technique to Assay Locomotor Activity in Drosophila.” Journal of Visualized Experiments, (192).

6. Meng H., Suenaga T., et al. (2021). “MHCI Deficiency and ADHD-like Symptoms.” Brain, Behavior, and Immunity, 97: 22–31.

7. Imai Y., Meng H., et al. (2019). “Twin CHCH Proteins in Neurodegeneration.” International Journal of Molecular Sciences, 20(4).

Conclusion

In summary, Dr. Hongrui Meng is a pioneering researcher with a global academic background, extensive project leadership, and a deep commitment to solving pressing neurological challenges. His work bridges molecular mechanisms and therapeutic development, contributing to both academic knowledge and patient care. His patents, publications, and collaborative efforts with pharmaceutical and medical technology sectors demonstrate his holistic and impactful approach to neuroscience. Dr. Meng’s dedication and scientific excellence make him a deserving candidate for recognition through the Excellence in Research Award.